Combination Treatment in Ulcerative Colitis using 5-Aminosalysilic Acid (5-ASA) and Polysaccharide Peptide of Indonesian Ganoderma lucidum Mycelium Extract
Background: Inflammatory bowel disease (IBD) is idiopathic disease characterized by chronic inflammation of the gastrointestinal tract. Polysaccharide peptide of Ganoderma lucidum mycelium extract (PPGL) is considerably a good option for adjunctive therapy of IBD. This study aims to evaluate the be...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2023-04-01
|
| Series: | The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy |
| Subjects: | |
| Online Access: | https://www.ina-jghe.com/index.php/jghe/article/view/899 |
| _version_ | 1797810487062167552 |
|---|---|
| author | Marcellus Simadibrata Aditya Rachman Felix Budimutiar Paulus Simadibrata Murdani Abdullah Raja Mangatur Haloho Anthony Eka Wijaya Batara Bisuk Shabrina Maharani Dewi Mustikarani Daniel Martin Simadibrata Peter Sugita |
| author_facet | Marcellus Simadibrata Aditya Rachman Felix Budimutiar Paulus Simadibrata Murdani Abdullah Raja Mangatur Haloho Anthony Eka Wijaya Batara Bisuk Shabrina Maharani Dewi Mustikarani Daniel Martin Simadibrata Peter Sugita |
| author_sort | Marcellus Simadibrata |
| collection | DOAJ |
| description | Background: Inflammatory bowel disease (IBD) is idiopathic disease characterized by chronic inflammation of the gastrointestinal tract. Polysaccharide peptide of Ganoderma lucidum mycelium extract (PPGL) is considerably a good option for adjunctive therapy of IBD. This study aims to evaluate the benefit of PPGL in patients treated with 5-ASA.
Method: A retrospective observational cohort study was conducted to examine the medical records of 124 ulcerative colitis patients. There were 80 patients in intervention group who were treated with a combination of 5-ASA and PPGL, and there were 44 patients in the control group who were treated with 5-ASA only. Clinical and laboratory endpoints were observed at the baseline and after 30, 60, and 90 days. Clinical endpoints included abdominal pain, bloody diarrhea, aphthous stomatitis, and polyarthritis; meanwhile, laboratory endpoints included hemoglobin level, ESR, CRP, fecal calprotectin, M2-pyruvate kinase (MP2K), fecal culture, C. difficile culture, and colonoscopy results. Clinical trials conducted after patient enrollment with registry number ClinicalTrials.gov NCT04029649.
Results: On day-30 there was a significant difference between intervention group 45.6% and control group 2.3% in abdominal pain complaints (p 0.001). Moreover, laboratory parameters of fecal calprotectin (p 0.001), fecal MP2K (p = 0.015), and hemoglobin (p 0.001) were considerably better in intervention group on day-30. These differences were consistently found on day 60 and 90.
Conclusion: The study implies potential correlation between PPGL administration and improvement of clinical and laboratory endpoints up to 90 days. A larger randomized, blinded, prospective study is required to confirm these effects in ulcerative colitis. |
| first_indexed | 2024-03-13T07:09:32Z |
| format | Article |
| id | doaj.art-5140c87312d64ba2a6423fbf83e970ce |
| institution | Directory Open Access Journal |
| issn | 1411-4801 2302-8181 |
| language | English |
| last_indexed | 2024-03-13T07:09:32Z |
| publishDate | 2023-04-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy |
| spelling | doaj.art-5140c87312d64ba2a6423fbf83e970ce2023-06-06T04:45:45ZengInterna PublishingThe Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy1411-48012302-81812023-04-0124121110.24871/24120232-11816Combination Treatment in Ulcerative Colitis using 5-Aminosalysilic Acid (5-ASA) and Polysaccharide Peptide of Indonesian Ganoderma lucidum Mycelium ExtractMarcellus Simadibrata0Aditya Rachman1Felix Budimutiar2Paulus Simadibrata3Murdani Abdullah4Raja Mangatur Haloho5Anthony Eka Wijaya6Batara Bisuk7Shabrina Maharani8Dewi Mustikarani9Daniel Martin Simadibrata10Peter Sugita11Division of Gastroenterology , Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, JakartaDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, JakartaDepartment of Internal Medicine, Abdi Waluyo Hospital, JakartaDepartment of Internal Medicine, Abdi Waluyo Hospital, JakartaDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, JakartaDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, JakartaDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, JakartaDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, JakartaDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, JakartaDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, JakartaFaculty of Medicine, Universitas Indonesia, JakartaPT. Sahabat Lingkungan Hidup, SurabayaBackground: Inflammatory bowel disease (IBD) is idiopathic disease characterized by chronic inflammation of the gastrointestinal tract. Polysaccharide peptide of Ganoderma lucidum mycelium extract (PPGL) is considerably a good option for adjunctive therapy of IBD. This study aims to evaluate the benefit of PPGL in patients treated with 5-ASA. Method: A retrospective observational cohort study was conducted to examine the medical records of 124 ulcerative colitis patients. There were 80 patients in intervention group who were treated with a combination of 5-ASA and PPGL, and there were 44 patients in the control group who were treated with 5-ASA only. Clinical and laboratory endpoints were observed at the baseline and after 30, 60, and 90 days. Clinical endpoints included abdominal pain, bloody diarrhea, aphthous stomatitis, and polyarthritis; meanwhile, laboratory endpoints included hemoglobin level, ESR, CRP, fecal calprotectin, M2-pyruvate kinase (MP2K), fecal culture, C. difficile culture, and colonoscopy results. Clinical trials conducted after patient enrollment with registry number ClinicalTrials.gov NCT04029649. Results: On day-30 there was a significant difference between intervention group 45.6% and control group 2.3% in abdominal pain complaints (p 0.001). Moreover, laboratory parameters of fecal calprotectin (p 0.001), fecal MP2K (p = 0.015), and hemoglobin (p 0.001) were considerably better in intervention group on day-30. These differences were consistently found on day 60 and 90. Conclusion: The study implies potential correlation between PPGL administration and improvement of clinical and laboratory endpoints up to 90 days. A larger randomized, blinded, prospective study is required to confirm these effects in ulcerative colitis.https://www.ina-jghe.com/index.php/jghe/article/view/899ulcerative colitisβ-1,3/1,6-d-glucanganoderma lucidum |
| spellingShingle | Marcellus Simadibrata Aditya Rachman Felix Budimutiar Paulus Simadibrata Murdani Abdullah Raja Mangatur Haloho Anthony Eka Wijaya Batara Bisuk Shabrina Maharani Dewi Mustikarani Daniel Martin Simadibrata Peter Sugita Combination Treatment in Ulcerative Colitis using 5-Aminosalysilic Acid (5-ASA) and Polysaccharide Peptide of Indonesian Ganoderma lucidum Mycelium Extract The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy ulcerative colitis β-1,3/1,6-d-glucan ganoderma lucidum |
| title | Combination Treatment in Ulcerative Colitis using 5-Aminosalysilic Acid (5-ASA) and Polysaccharide Peptide of Indonesian Ganoderma lucidum Mycelium Extract |
| title_full | Combination Treatment in Ulcerative Colitis using 5-Aminosalysilic Acid (5-ASA) and Polysaccharide Peptide of Indonesian Ganoderma lucidum Mycelium Extract |
| title_fullStr | Combination Treatment in Ulcerative Colitis using 5-Aminosalysilic Acid (5-ASA) and Polysaccharide Peptide of Indonesian Ganoderma lucidum Mycelium Extract |
| title_full_unstemmed | Combination Treatment in Ulcerative Colitis using 5-Aminosalysilic Acid (5-ASA) and Polysaccharide Peptide of Indonesian Ganoderma lucidum Mycelium Extract |
| title_short | Combination Treatment in Ulcerative Colitis using 5-Aminosalysilic Acid (5-ASA) and Polysaccharide Peptide of Indonesian Ganoderma lucidum Mycelium Extract |
| title_sort | combination treatment in ulcerative colitis using 5 aminosalysilic acid 5 asa and polysaccharide peptide of indonesian ganoderma lucidum mycelium extract |
| topic | ulcerative colitis β-1,3/1,6-d-glucan ganoderma lucidum |
| url | https://www.ina-jghe.com/index.php/jghe/article/view/899 |
| work_keys_str_mv | AT marcellussimadibrata combinationtreatmentinulcerativecolitisusing5aminosalysilicacid5asaandpolysaccharidepeptideofindonesianganodermalucidummyceliumextract AT adityarachman combinationtreatmentinulcerativecolitisusing5aminosalysilicacid5asaandpolysaccharidepeptideofindonesianganodermalucidummyceliumextract AT felixbudimutiar combinationtreatmentinulcerativecolitisusing5aminosalysilicacid5asaandpolysaccharidepeptideofindonesianganodermalucidummyceliumextract AT paulussimadibrata combinationtreatmentinulcerativecolitisusing5aminosalysilicacid5asaandpolysaccharidepeptideofindonesianganodermalucidummyceliumextract AT murdaniabdullah combinationtreatmentinulcerativecolitisusing5aminosalysilicacid5asaandpolysaccharidepeptideofindonesianganodermalucidummyceliumextract AT rajamangaturhaloho combinationtreatmentinulcerativecolitisusing5aminosalysilicacid5asaandpolysaccharidepeptideofindonesianganodermalucidummyceliumextract AT anthonyekawijaya combinationtreatmentinulcerativecolitisusing5aminosalysilicacid5asaandpolysaccharidepeptideofindonesianganodermalucidummyceliumextract AT batarabisuk combinationtreatmentinulcerativecolitisusing5aminosalysilicacid5asaandpolysaccharidepeptideofindonesianganodermalucidummyceliumextract AT shabrinamaharani combinationtreatmentinulcerativecolitisusing5aminosalysilicacid5asaandpolysaccharidepeptideofindonesianganodermalucidummyceliumextract AT dewimustikarani combinationtreatmentinulcerativecolitisusing5aminosalysilicacid5asaandpolysaccharidepeptideofindonesianganodermalucidummyceliumextract AT danielmartinsimadibrata combinationtreatmentinulcerativecolitisusing5aminosalysilicacid5asaandpolysaccharidepeptideofindonesianganodermalucidummyceliumextract AT petersugita combinationtreatmentinulcerativecolitisusing5aminosalysilicacid5asaandpolysaccharidepeptideofindonesianganodermalucidummyceliumextract |